Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.13 USD | -1.35% | -0.83% | -12.47% |
Jun. 03 | UroGen Pharma Appoints David Lin as New Chief Commercial Officer | CI |
May. 14 | Oppenheimer Lowers UroGen Pharma Price Target to $32 From $34, Maintains Outperform Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.47% | 474M | |
+15.55% | 121B | |
+12.66% | 107B | |
-2.53% | 24.82B | |
+1.19% | 22.48B | |
-9.70% | 18.32B | |
-42.28% | 16.33B | |
-18.92% | 15.31B | |
+6.19% | 14.08B | |
+28.83% | 11.74B |
- Stock Market
- Equities
- URGN Stock
- News UroGen Pharma Ltd.
- Jefferies Downgrades UroGen Pharma to Hold From Buy, Adjusts Price Target to $10 From $35